Samsung Biologics will join the Coalition for Epidemic Preparedness Innovations (CEPI) Vaccine Manufacturing Facility Network to create a ‘ready‑to‑activate’ recombinant‑protein vaccine manufacturing process for pandemic response, the partners announced. Samsung will develop mammalian cell–based workflows, run outbreak simulation exercises and prepare regulatory dossiers to compress activation timelines. The initial budget for the collaboration is $20 million; Samsung committed to produce 50 million vaccine doses during an activation and provide CEPI with one billion doses of drug substance ready for conversion into finished vaccines. CEPI framed the work as directly supporting its 100‑Days Mission to enable vaccine deployment within 100 days of identifying a novel pathogen. The agreement also includes tech transfer and regulatory preparedness measures designed to reduce the time from sequence identification to large‑scale manufacturing and filing.